Alexion Pharma (ALXN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports First Quarter 2016 Results
April 28, 2016 6:30 AM EDTTotal Revenues of $701 Million; Increased 17 Percent Year-on-Year; 22 Percent Increase Year-on-Year on a Constant Currency Basis
Soliris® (eculizumab) Revenues Driven by Steady Number of New Patients Treated in the U.S., Europe and Japan
Strensiq® (asfotase alfa) Launch Off to a Strong Start in Initial Countries
Kanuma® (sebelipase alfa) U.S. Launch Under Way
Exceeded Target Enrollment for Two Initial Studies of ALXN1210 in Patients with PNH
Commenced Dose Escalation for SBC-103 in Phase 1/2 Study in Patients with MPS IIIB
Progressed Three Registration Studies... More
